{
    "2020-08-10": [
        [
            {
                "time": "",
                "original_text": "近九成营收靠代理？重磅疫苗代理协议将到期，智飞生物遭遇续签考验",
                "features": {
                    "keywords": [
                        "智飞生物",
                        "疫苗代理",
                        "协议到期",
                        "续签考验"
                    ],
                    "sentiment_score": -0.6,
                    "policy_related": "false",
                    "investment_strategy": "true",
                    "sector_focus": [
                        "医药",
                        "生物"
                    ],
                    "causal_factor": "true",
                    "causal_impact": "negative",
                    "affected_by_time_series": "true",
                    "ts_effect_direction": "negative"
                }
            },
            {
                "time": "",
                "original_text": "智飞生物：湖南省疫苗临床试验示范基地揭牌",
                "features": {
                    "keywords": [
                        "智飞生物",
                        "疫苗",
                        "临床试验",
                        "示范基地"
                    ],
                    "sentiment_score": 0.7,
                    "policy_related": "false",
                    "investment_strategy": "false",
                    "sector_focus": [
                        "医药",
                        "生物"
                    ],
                    "causal_factor": "true",
                    "causal_impact": "positive",
                    "affected_by_time_series": "true",
                    "ts_effect_direction": "positive"
                }
            },
            {
                "time": "2020-07",
                "original_text": "2020年7月疫苗批签发数据：批签发维持高速增长 流感疫苗恢复批签发",
                "features": {
                    "keywords": [
                        "疫苗",
                        "批签发",
                        "高速增长",
                        "流感疫苗"
                    ],
                    "sentiment_score": 0.8,
                    "policy_related": "false",
                    "investment_strategy": "true",
                    "sector_focus": [
                        "医药",
                        "生物"
                    ],
                    "causal_factor": "true",
                    "causal_impact": "positive",
                    "affected_by_time_series": "true",
                    "ts_effect_direction": "positive"
                }
            },
            {
                "time": "",
                "original_text": "智飞生物现1笔大宗交易 共成交320.36万元",
                "features": {
                    "keywords": [
                        "智飞生物",
                        "大宗交易",
                        "成交金额"
                    ],
                    "sentiment_score": 0.5,
                    "policy_related": "false",
                    "investment_strategy": "true",
                    "sector_focus": [
                        "医药",
                        "生物"
                    ],
                    "causal_factor": "true",
                    "causal_impact": "neutral",
                    "affected_by_time_series": "true",
                    "ts_effect_direction": "neutral"
                }
            },
            {
                "time": "",
                "original_text": "机构重仓股跟踪周报",
                "features": {
                    "keywords": [
                        "机构重仓",
                        "跟踪周报"
                    ],
                    "sentiment_score": 0.4,
                    "policy_related": "false",
                    "investment_strategy": "true",
                    "sector_focus": [
                        "综合"
                    ],
                    "causal_factor": "false",
                    "causal_impact": "neutral",
                    "affected_by_time_series": "true",
                    "ts_effect_direction": "neutral"
                }
            },
            {
                "time": "",
                "original_text": "医药生物行业周报：中报窗口期继续看好业绩高增长板块 持续推荐有实力能兑现的疫苗公司",
                "features": {
                    "keywords": [
                        "医药生物",
                        "中报",
                        "业绩高增长",
                        "疫苗公司"
                    ],
                    "sentiment_score": 0.9,
                    "policy_related": "false",
                    "investment_strategy": "true",
                    "sector_focus": [
                        "医药",
                        "生物"
                    ],
                    "causal_factor": "true",
                    "causal_impact": "positive",
                    "affected_by_time_series": "true",
                    "ts_effect_direction": "positive"
                }
            },
            {
                "time": "",
                "original_text": "医药行业周报：建议关注药店 关注业绩高增长、政策变化和估值性性价比",
                "features": {
                    "keywords": [
                        "医药行业",
                        "药店",
                        "业绩高增长",
                        "政策变化",
                        "估值性性价比"
                    ],
                    "sentiment_score": 0.7,
                    "policy_related": "true",
                    "investment_strategy": "true",
                    "sector_focus": [
                        "医药"
                    ],
                    "causal_factor": "true",
                    "causal_impact": "positive",
                    "affected_by_time_series": "true",
                    "ts_effect_direction": "positive"
                }
            },
            {
                "time": "",
                "original_text": "医药行业周报：维持行业长期看好观点 积极关注新冠疫苗研发动态",
                "features": {
                    "keywords": [
                        "医药行业",
                        "长期看好",
                        "新冠疫苗",
                        "研发动态"
                    ],
                    "sentiment_score": 0.8,
                    "policy_related": "false",
                    "investment_strategy": "true",
                    "sector_focus": [
                        "医药"
                    ],
                    "causal_factor": "true",
                    "causal_impact": "positive",
                    "affected_by_time_series": "true",
                    "ts_effect_direction": "positive"
                }
            },
            {
                "time": "",
                "original_text": "时代医药周报 | 武汉出台重点监控目录，辅助用药限量降价大势所趋",
                "features": {
                    "keywords": [
                        "时代医药",
                        "武汉",
                        "重点监控",
                        "辅助用药",
                        "限量降价"
                    ],
                    "sentiment_score": -0.5,
                    "policy_related": "true",
                    "investment_strategy": "false",
                    "sector_focus": [
                        "医药"
                    ],
                    "causal_factor": "true",
                    "causal_impact": "negative",
                    "affected_by_time_series": "true",
                    "ts_effect_direction": "negative"
                }
            },
            {
                "time": "",
                "original_text": "全球新冠疫苗最新进展，最快或将年底获批",
                "features": {
                    "keywords": [
                        "新冠疫苗",
                        "最新进展",
                        "年底获批"
                    ],
                    "sentiment_score": 0.8,
                    "policy_related": "false",
                    "investment_strategy": "true",
                    "sector_focus": [
                        "医药",
                        "生物"
                    ],
                    "causal_factor": "true",
                    "causal_impact": "positive",
                    "affected_by_time_series": "true",
                    "ts_effect_direction": "positive"
                }
            },
            {
                "time": "",
                "original_text": "恒瑞医药半年盈逾26亿拔得头筹，市盈率仍远低于行业均值",
                "features": {
                    "keywords": [
                        "恒瑞医药",
                        "半年盈利",
                        "市盈率",
                        "行业均值"
                    ],
                    "sentiment_score": 0.7,
                    "policy_related": "false",
                    "investment_strategy": "true",
                    "sector_focus": [
                        "医药"
                    ],
                    "causal_factor": "true",
                    "causal_impact": "positive",
                    "affected_by_time_series": "true",
                    "ts_effect_direction": "positive"
                }
            },
            {
                "time": "",
                "original_text": "社保基金现身54股，青睐消费医药和制造业",
                "features": {
                    "keywords": [
                        "社保基金",
                        "消费医药",
                        "制造业"
                    ],
                    "sentiment_score": 0.6,
                    "policy_related": "false",
                    "investment_strategy": "true",
                    "sector_focus": [
                        "医药",
                        "制造"
                    ],
                    "causal_factor": "true",
                    "causal_impact": "positive",
                    "affected_by_time_series": "true",
                    "ts_effect_direction": "positive"
                }
            }
        ]
    ]
}